Low Serum Alanine Aminotransferase Blood Activity Is Associated with Shortened Survival of Renal Cell Cancer Patients and Survivors: Retrospective Analysis of 1830 Patients.

Autor: Laufer M; Department of Urology, Chaim Sheba Medical Center, Ramat Gan 5266202, Israel.; Faculty of Health and Medical Sciences, Tel-Aviv University, Tel-Aviv 6997801, Israel., Sarfaty M; Institute of Oncology, Chaim Sheba Medical Center, Ramat Gan 5266202, Israel., Jacobi E; Faculty of Medicine, Ben-Gurion University, Beer-Sheva 8410501, Israel., Itelman E; Cardiology Division, Rabin Medical Center, Beilenson Campus, Peta-Tiqva 4941492, Israel.; Department of Internal Medicine E, Rabin Medical Center, Beilenson Campus, Peta-Tiqva 4941492, Israel., Segal G; Education Authority, Chaim Sheba Medical Center, Ramat Gan 5266202, Israel., Perelman M; Department of Internal Medicine 'I', Chaim Sheba Medical Center, Ramat Gan 5266202, Israel.
Jazyk: angličtina
Zdroj: Journal of clinical medicine [J Clin Med] 2024 Oct 07; Vol. 13 (19). Date of Electronic Publication: 2024 Oct 07.
DOI: 10.3390/jcm13195960
Abstrakt: Background: Sarcopenia is characterized by a loss of muscle mass and function and is often associated with frailty, a syndrome linked to physical disability and shortened survival in various patient populations, including cancer patients. Low serum alanine aminotransferase (ALT) values, serving as a biomarker for sarcopenia, were previously associated with frailty and shortened survival in several cancers. In the current study, we aimed to test the association between low ALT and shorter survival in renal cell carcinoma (RCC) patients and survivors. Methods: This was a retrospective analysis of RCC patients and survivors, both in- and outpatients. We defined patients with sarcopenia as those presenting with ALT < 17 IU/L. Results: We identified records of 3012 RCC patients. The cohort included 1830 patients (mean age 65.6 ± 13.3 years, 68% were men) of whom only 179 underwent surgical treatment. Out of the eligible cohort, 811 patients (44.3%) had ALT < 17 IU/L, with a mean ALT value of patients within the low-ALT group of 11.79 IU/L, while the mean value in the higher ALT level group was 24.44 IU/L ( p < 0.001). Patients in the low-ALT group were older (67.9 vs. 63.7 years; p < 0.001) and had lower BMIs (26.6 vs. 28; p < 0.001). In addition, patients with low ALT had lower hemoglobin values (12.14 vs. 12.91 g/dL; p < 0.001), higher serum creatinine (1.49 vs. 1.14; p < 0.001) and higher platelet to lymphocyte ratios (178 vs. 156; p < 0.001). In a univariate analysis, low ALT levels were associated with a 72% increase in mortality (95% CI 1.46-2.02, p < 0.001). In a multivariate model controlled for age, gender, hemoglobin, platelets, LDH, neutrophil to lymphocyte ratios and platelet to lymphocyte ratios, low ALT levels were still associated with a 27% increase in mortality (HR = 1.27, 95% CI 1.08-1.51; p = 0.005). Conclusion. Low ALT values, associated with sarcopenia and frailty, are also associated with shortened survival in RCC patients, and survivors and could potentially be applied for optimizing individual treatment decisions.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje